TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer
- PMID: 24336330
- DOI: 10.1038/onc.2013.527
TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer
Abstract
Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine with the capability to act as tumour suppressor or tumour promoter depending on the cellular context. TGF-beta receptor type-2 (TGFBR2) is the ligand-binding receptor for all members of the TGF-β family. Data from mouse model experiments demonstrated that loss of Tgfbr2 expression in mammary fibroblasts was linked to tumour initiation and metastasis. Using a randomised tamoxifen trial cohort including in total 564 invasive breast carcinomas, we examined TGFBR2 expression (n=252) and phosphorylation level of downstream target SMAD2 (pSMAD2) (n=319) in cancer-associated fibroblasts (CAFs) and assessed links to clinicopathological markers, prognostic and treatment-predictive values. The study revealed that CAF-specific TGFBR2 expression correlated with improved recurrence-free survival. Multivariate analysis confirmed CAF-TGFBR2 to be an independent prognostic marker (multivariate Cox regression, hazard ratio: 0.534, 95% (CI): 0.360-0.793, P=0.002). CAF-specific pSMAD2 levels, however, did not associate with survival outcome. Experimentally, TGF-β signalling in fibroblasts was modulated using a TGF-β ligand and inhibitor or through lentiviral short hairpin RNA-mediated TGFBR2-specific knockdown. To determine the role of fibroblastic TGF-β pathway on breast cancer cells, we used cell contact-dependent cell growth and clonogenicity assays, which showed that knockdown of TGFBR2 in CAFs resulted in increased cell growth, proliferation and clonogenic survival. Further, in a mouse model transfected CAFs were co-injected with MCF7 and tumour weight and proportion was monitored. We found that mouse xenograft tumours comprising TGFBR2 knockdown fibroblasts were slightly bigger and displayed increased tumour cell capacity. Overall, our data demonstrate that fibroblast-related biomarkers possess clinically relevant information and that fibroblasts confer effects on breast cancer cell growth and survival. Regulation of tumour-stromal cross-talk through fibroblastic TGF-β pathway may depend on fibroblast phenotype, emphasising the importance to characterise tumour microenvironment subtypes.
Similar articles
-
Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production.Cell Cycle. 2012 Aug 15;11(16):3019-35. doi: 10.4161/cc.21384. Epub 2012 Aug 9. Cell Cycle. 2012. PMID: 22874531 Free PMC article.
-
Absence of transforming growth factor-beta type II receptor is associated with poorer prognosis in HER2-negative breast tumours.Ann Oncol. 2010 Apr;21(4):734-740. doi: 10.1093/annonc/mdp518. Epub 2009 Nov 13. Ann Oncol. 2010. PMID: 19914962
-
A reciprocal role of prostate cancer on stromal DNA damage.Oncogene. 2014 Oct 9;33(41):4924-31. doi: 10.1038/onc.2013.431. Epub 2013 Oct 21. Oncogene. 2014. PMID: 24141771 Free PMC article.
-
Two faces of TGF-beta1 in breast cancer.Mediators Inflamm. 2014;2014:141747. doi: 10.1155/2014/141747. Epub 2014 May 7. Mediators Inflamm. 2014. PMID: 24891760 Free PMC article. Review.
-
TGFBR1 and cancer susceptibility.Trans Am Clin Climatol Assoc. 2014;125:300-12. Trans Am Clin Climatol Assoc. 2014. PMID: 25125747 Free PMC article. Review.
Cited by
-
Associations of the Transforming Growth Factor β/Smad Pathway, Body Mass Index, and Physical Activity With Breast Cancer Outcomes: Results From the Shanghai Breast Cancer Study.Am J Epidemiol. 2016 Oct 1;184(7):501-509. doi: 10.1093/aje/kww015. Epub 2016 Sep 19. Am J Epidemiol. 2016. PMID: 27651382 Free PMC article.
-
Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer.Oncotarget. 2016 Nov 22;7(47):76920-76933. doi: 10.18632/oncotarget.12729. Oncotarget. 2016. PMID: 27764775 Free PMC article.
-
Crosstalk and plasticity driving between cancer-associated fibroblasts and tumor microenvironment: significance of breast cancer metastasis.J Transl Med. 2023 Nov 17;21(1):827. doi: 10.1186/s12967-023-04714-2. J Transl Med. 2023. PMID: 37978384 Free PMC article. Review.
-
Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance.Cell Oncol (Dordr). 2018 Aug;41(4):353-367. doi: 10.1007/s13402-018-0388-2. Epub 2018 Jul 19. Cell Oncol (Dordr). 2018. PMID: 30027403 Review.
-
Biological Effects of Human Exposure to Environmental Cadmium.Biomolecules. 2022 Dec 24;13(1):36. doi: 10.3390/biom13010036. Biomolecules. 2022. PMID: 36671421 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous